Related Experiment Video
Updated: May 10, 2025
07:13
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
13.1K
Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment
Manoj Soman1,2, Apoorva Jadhav1,2, Abhaya Balakrishnan1,2
1Department of Vitreoretinal Services, Chaithanya Eye Hospital and Research Institute, Trivandrum, India.
Clinical Ophthalmology (Auckland, N.Z.)
|April 24, 2025
Summary
Brolucizumab treatment for nAMD and PCV showed a 4.9% intraocular inflammation (IOI) rate. Proactive monitoring and early intervention with steroids led to favorable visual outcomes, supporting Brolucizumab
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Intravitreal anti-VEGF agents are vital for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
- Brolucizumab offers extended duration and fewer injections but carries a risk of intraocular inflammation (IOI).
- Resistant nAMD and PCV cases require careful management strategies.
Purpose of the Study:
- To evaluate the outcomes of a proactive monitoring protocol for Brolucizumab-treated eyes with resistant nAMD and PCV.
- To assess the incidence and management of intraocular inflammation (IOI) associated with Brolucizumab therapy.
- To determine the visual outcomes in patients undergoing proactive monitoring for Brolucizumab-associated IOI.
Main Methods:
- Retrospective analysis of patients treated with Brolucizumab for resistant nAMD and PCV at a single center.
- Implementation of a proactive monitoring protocol including telephonic follow-up and mandatory clinic visits.
- Data collection on demographics, visual outcomes, IOI incidence, management strategies, and follow-up adherence.
Main Results:
- A total of 311 Brolucizumab injections were given to 144 eyes over a mean follow-up of 8.6 months.
- Intraocular inflammation (IOI) occurred in 4.9% of eyes (7/144), with a mean onset of 32.1 days post-injection.
- IOI was managed effectively with topical/oral steroids, leading to resolution without requiring intravitreal agents or vitrectomy; visual acuity remained stable or improved in most cases.
Conclusions:
- Proactive monitoring is crucial for managing Brolucizumab-associated intraocular inflammation (IOI) in nAMD and PCV.
- Early intervention with corticosteroids effectively manages Brolucizumab-induced IOI, leading to favorable visual outcomes.
- Brolucizumab can be safely used in resistant nAMD and PCV cases when managed with a careful monitoring and treatment protocol.
